Therefore, the National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer (NSCLC) recommend that testing should be conducted as part of broad molecular profiling to detect ERBB2 mutations in newly diagnosed patients and Ado-trastuzumab emtansine and Trastuzumab deruxtecan are available targeted agents in ERBB2-mutated NSCLC. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.